AI Article Synopsis
- Atopic dermatitis and psoriasis are common chronic skin conditions that can greatly impact quality of life, but biologic treatments have led to significant improvements in managing these diseases.
- There's a surprising phenomenon where treatment can cause patients to develop features of the other condition while undergoing biologic therapy.
- The text presents two cases: one where a psoriasis lesion appeared in a patient with atopic dermatitis treated with dupilumab, and another where an eczematoid lesion arose in a patient with ankylosing spondylitis treated with Secukinumab.
Article Abstract
Atopic dermatitis and psoriasis are both common chronic inflammatory skin conditions that can significantly affect the quality of life for individuals affected by them. With the growing use of biologic agents, there have been remarkable clinical advancements in the treatment of these diseases. Interestingly, during biologic therapy for either condition, a phenomenon has emerged where treatment can paradoxically induce a transition to the phenotype of the other condition.We present two cases of immune drift phenomena caused by biologic agents for treating psoriasis and atopic dermatitis.The first one is a case of psoriasis lesion that developed in an old patient with AD who was treated with dupilumab for two months. The second one is a case of eczematoid lesion that developed in an adult patient with ankylosing spondylitis who was treated with Secukinumab for 1 year.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10712341 | PMC |
| http://dx.doi.org/10.2147/CCID.S445468 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!